Call for Abstracts

Abstract Submission Dates

Abstract Submissions Open: Wednesday, July 16, 2025
Abstract Submissions Close: Wednesday, October 1, 2025, at 2:00 PM ET
Abstract Dispositions Sent: Wednesday, October 22, 2025
Acceptance & Registration Deadline: Friday, November 21, 2025

Submissions are now closed.

Special Call: New Antimicrobial Agents Session

In addition to the general abstract submissions, IMARI 2026 will feature a New Antimicrobial Agents Session, taking place January 28–30, 2026, in Las Vegas, NV. This session will highlight antibacterial (including Mycobacteria) and antifungal projects that are in or entering clinical development.

Key Submission Details

Submission Deadline: December 1, 2025, by 2:00 p.m. ET
Notification of Acceptance: By December 17, 2025
All selection decisions are final and not subject to appeal.

Eligibility Requirements

A novel compound must be presented.
For small molecules, the chemical structure must be shown during the presentation.
IND-enabling toxicology studies must have been completed for the compound, with a sufficient safety margin demonstrated.
The project is currently in or entering clinical development.
The compound has company approval for public disclosure and is at least scheduled for Phase I development.
The presentation must be data-driven.
If accepted, the presenter will deliver an oral presentation during the New Antimicrobial Agents session in addition to a poster presentation.

Submission Instructions

To apply, please complete the application form. This submission also serves as the abstract submission for the overview of compound attributes; no separate submission through the General Abstract Submission process is required.

Accessing the Abstract Submission Site

The American Society for Microbiology (ASM) is hosting the IMARI abstract submissions site. To submit an abstract, users must log in through the ASM Single Sign-On (SSO) system. This login system enhances security and ensures that your information and submissions are protected.

Important details:

A user account is required to log in and access the abstract submission platform.
Creating an account is complimentary and there is no fee to create an account.
Individuals are not required to be an ASM or Infectious Diseases Society of America (IDSA) member to submit an abstract or create a user account.
Individuals only need one password for a user account which will be utilized across all IMARI services, including registration.

This secure system assists ASM and IDSA to verify users’ identities and ensures reliable communication throughout the abstract submission and review process. If you do not have an ASM user account, you will be prompted to create one prior to logging into the abstract submission site.

Abstract submissions are now closed.

Abstract Submission Topics

The IMARI 2026 Program Committee is accepting abstracts on the following topics:

β-lactamases
Early Clinical Studies
Mechanisms of Resistance in Fungi
Mechanisms of Resistance in Gram Negative Bacteria
Mechanisms of Resistance in Gram Positive Bacteria
Mycobacteriology
New Antibacterials and Mechanisms of Action
New Antifungals
New Targets
Novel Diagnostics for AMR
Non-Traditional Approaches for AMR
PK/PD Antibacterial and Antifungals
Epidemiology and Surveillance

Abstract Submission Policies and Guidelines

Abstract Disposition

Submitters will be notified of their abstract disposition via email on October 22, 2025.

Maximum abstracts you can submit

A maximum of two abstracts may be submitted per presenting author. The presenting author is the individual who submits the abstract and will deliver the poster or oral presentation, as selected by the Program Committee.

Abstract eligibility requirements

The abstract is based on results that have not been published and will not be published in any journal prior to January 30, 2026. The abstract has also not been presented, and will not be presented, at any national or international scientific conference before that date.

Author awareness

All authors listed on the abstract are aware of and have approved their inclusion in the submission.

Presenting author requirements

If the abstract is withdrawn after November 22, 2025, if no author appears to present the accepted abstract, or if a change in the presenting author is not communicated to ASM and IDSA, the presenting author may be prohibited from presenting at ASM or IDSA-sponsored meetings for up to three years.

Abstract rights

Upon acceptance, ASM and IDSA will retain the rights to any print or electronic compilation of conference abstracts, in accordance with ASM and IDSA’s copyright policy.

Commercially funded research

If the research presented is funded by a commercial company, the content will be based on accepted scientific principles and methods and will not promote the commercial interests of the funding entity.

Abstract content

All content, including the presentation of therapeutic options, will be well-balanced, evidence-based, and free of commercial bias.

Promotional content

If the presenting author has received training or served as a speaker on behalf of a commercial entity (e.g., speaker’s bureau), no promotional content from those engagements will be included in the presentation.

Discussion of off-label products

If discussing any product use that is off-label, the presenting author will clearly disclose that the use or indication is not currently approved by the FDA for labeling or advertising.

AI guidelines

Authors are required to disclose any use of AI tools (e.g., for language editing, data analysis, or content generation). All submitted work must be original. The use of AI-generated content is prohibited unless it reviewed and verified by the authors for accuracy and appropriateness. Content that lacks sufficient human oversight and validation will not be accepted.

Presentations will be monitored

All presentations will be monitored to be sure that they are educational and not commercial in nature.

Live presentation requirements

By submitting an abstract, the presenting author agrees to participate in a live, in-person meeting format if their abstract is selected. No virtual presentation options will be available.

Presenting author must be registered for IMARI 2026

The presenting author must be registered for IMARI 2026 by November 22, 2025. Failure to register by this date will result in withdrawal of the abstract.

Extensions

No extensions will be granted beyond the posted deadlines.